£35 million rights issue for SkyePharma
In November 2005, counseled SkyePharma Plc, an official listed UK pharmaceutical, biotechnology and drug delivery public company, concerning a 1 for 5 rights issue. This raised approximately £35 million needed for the further development of the Company's lead pipeline asthma treatment, Flutiform.